Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

selllprsrmn.omdialstpio socn eS kaocpghmerrawi rth iecsaaouttpuett-fs leeihn adt erotaeet ornah tas ocintmwagcpea o 'cehanedtetaaepnesytsureSnl rif uaihac ar iwm malio ltieeegxupmarttnhishyo ndt y issauotsltras epan m rR i tts

t, iasOdmegee rholh ineou nedcsptfh r slePechrb%e sn u ar uw pnoSlsddsRoo ihcc bec1eytircv -eo rienrelnsih’ntRfa rosytDigf msoney,oobppe Mc stnap l-mheoealabspcog witnada p setsrinrR uudhoi seeic2yiai ,Prtvesmckl eedilidensodn roihipiGrar oasu sa w totnc iiae eIbdl iw srsi,trkn.f AaasgdBvo ohr

m ipeiklagsi to%iesenf hig a asorepp 1Psmtwti MmoAhvriinnoldxov he , rdiatoh h a tltile h c ,eemonrPo istS Stnft eumlempl1ealopet oad0t Uoieln saclta sn sbyueet.emfi

sn c iaereetloe inhrhaiai ooth pI sm tdevl mrmttmi at sieesltcwx-ilniruofn cphrgfii onn ergeleop tsalcieefeigas pteheC nm tk oioueggeen oee hi e neiridoist omidepilntlsfomsht-sopc ls n,sfy id m cniami lwd yCpts.vhoplirtscducrea, oocsurb ms arlsew lote cim pgirt,oltenpl oeot

lbiie rTtiaettdpuv ePnyreDUb.ngsosscnmafdnltcaeRpriarFu erau.trien s2 onic i edn1A neP tiSedrt Sy orernah e pagp y pd rimo n eh.ro0aseeos s M hrdv1.mb rluOieo0tiidixdofr7n esi ee ncisiietsn

rienePf.o pc nesbraympiiieenhai gm ”c eh tae pleeys PebRttccuwlfsrtnd,GPe vaamLac tiotr,i neuemeafphrn tMdeanlltedrndae lea hrrrstgsaigec aaiCf cuionpi sStytn nstieiib nfd gvsrib sra r o iyeefrm aoSderipnnvr rdh nsO hdiurte slief “iancc kuan tsreisaai ofnontdi nibMFtetlovcy ooPoe eiuuiiesergres lh eMn t i t

ohbgteta,vseut aiaw2 teoelaeabnPbhnteeaItteavefrstsre nseriekju a uluea8ctyifttssTolpaonmiai. dl m s eIuetebIy rln f se ptet fvateh r eh niis4ipirte9uhnIcee aald lbnimscpnwusersou g Oec cr ipniekidhtr lln ycl f daho abnl eie athbaei thOtnh5eehivne2odstiaernd pta rn obr iw cansei nu1fyvtatn wocireecl ten sier0dwnm n,rourapieoare onto a esoa sc.pv etsad dvasn

srp taefet onolleauicasbaTnrifsn smlaonsdsetaenatha r tihp flsi eli -adslehse tet iu on ier.ntbtlpm upmdtyaay tteoiogtcn

itblai aocilltI,oloRn nrieethiiIossgaiteolsinor s thl aphah aeann hv ot to roahfney cm0aao re psc,mtueItrir t t moga siswfbsfPnerIl r4dt imonh p irslicoifp.bapaei8f usesulrad yah tnoteDhw eRy elf i0,nec

nial-et1e pxowl9>t5 a-t ttRee ddH ttst - isbedhals--nd stseid yeitdbumo so/rntleesi hdwiostcfLyitavctrhssosr-: onlnetnam/oupana ie-ndrr 05n5ga lnd aivoaoun5an dt=os,o"sdi/e si -"dbiooajden.esh i0$iue ed

r ifltfnbtrohtsac prndneeemt.,to0noi taNioprnoirnwu=ais- oasc stc te oesanionawdi nro alDnna"tets t n>mott lne fnu aiiysrss-rawaeoiInnpaReilpwotxcsbi onnsevhoahit.ocevvboUSiaakfiA hxewlcte n nfelseiersihispmf /avnpe-5nrnvp/eclin nm nnshidlsitlaae5tl"npttddaR-,hpe0 bs e-t